Spotlight on eltrombopag in the treatment of children with chronic immune thrombocytopenia

Abstract

Michele P Lambert,1,2 1Division of Hematology, The Children's Hospital of Philadelphia, 2Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA Abstract: Pediatric data on the use of thrombopoietin receptor agonists are fairly limited. The recent approval of eltrombopag by the US Food and Drug Administration for children aged ≥1 year, based on data from two randomized, placebo-controlled clinical trials, may lead to the increased use of this drug in clinical practice, and therefore, it is important to have a basic understanding of the biology, pharmacokinetics, safety, and efficacy of the medication. Keywords: ITP, pediatrics, treatment, thrombopoietin receptor agonists 

Keywords

• ITP
• Pediatrics
• Treatment
• Thrompoietin receptor agonists